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Abstract
Rational: While a variety of registered therapies exist for Cutaneous T Cell Lymphoma, no such therapy is available for
Cutaneous B Cell Therapy. In this context we performed a phase II, open label, multicenter, non-comparative study to
evaluate the efficacy and safety of repeated intra-lesional administrations of TG1042 (adenovirus-interferon-c) in patients
with relapsing primary cutaneous B-cell lymphomas (CBCL).
Method: Thirteen patients have been enrolled and received intralesional injections of TG1042 containing 561010 viral
particles into up to six lesions simultaneously. Injections were performed on days 1, 8 and 15 of each of four consecutive 28
day cycles.
Results: Eleven (85%) out of 13 enrolled patients showed an objective response after injections of TG1042. Seven patients
(54%) exhibited complete and four (31%) displayed partial response. The median time to disease progression in the study
population was 23.5 months (range 6.25 to 26+). Most commonly observed adverse events were minor to moderate flu-like
symptoms, fatigue and injection site reactions.
Conclusions: Our study showed that treatment with TG1042 was associated with a clinical benefit in the majority of the
patients with relapsing CBCL, including tumor regression, a clinically meaningful duration of response and a good treatment
tolerance.
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Introduction
Cutaneous lymphomas (CL) represent a heterogeneous group of
Non-Hodgkin’s lymphomas and are the second most frequent
extranodal lymphomas [1]. They are characterized by lympho-
proliferative clonal infiltrates of mainly T- or B-cell initially
appearing in the skin [2,3,4]. During progression of the disease,
the lesions can change shape, eventually forming plaques and
tumors before developing extracutaneous disease. The most
common type of cutaneous lymphoma is the cutaneous T-cell
lymphoma (CTCL). Primary cutaneous B-cell lymphomas
(CBCLs) with an incidence rate of approximately 3.1 per
190009000 persons and per year represent 20–25% of all
cutaneous lymphomas [5,6]. The most common CBCL subtypes
are: primary cutaneous follicular lymphoma (PCFL), primary
cutaneous marginal zone lymphoma (PCMZL), and diffuse large
B-cell lymphoma, leg-type [4].
While a variety of registered therapies exist for CTCL, no such
therapy is available for CBCL. For the management of relapsing
CBCL, after first line radiotherapy or surgery, various off-label
therapeutic options are being explored. Curative treatments
include radiotherapy and surgery, but disease relapses justify to
seek alternative therapeutics [7]. Immunotherapeutic approaches,
such as recombinant IFN-c and IFN-a have shown clinical efficacy
in this group of diseases. Systemic administration of IFN-c has
shown promising response rates in CTCL, however, therapy with
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recombinant cytokines is limited by their short half-life and
significant side effects upon systemic administration [8].
TG1042 is an adenovirus 5 expressing the cDNA of human
IFN-c gene. In the previously conducted phase I/II, open label,
multicenter, dose-escalation study, 38 CTCL and CBCL patients
received intra-tumoral injections of TG1042. Local tumor
response could be observed in all 5 treated CBCL patients, with
3 complete responses and 2 partial responses. TG1042 was well
tolerated with minor to moderate injection side reactions and flu-
like symptoms as most frequent adverse events [9,10].
Considering clinical responses in CBCL patients and absence of
approved medicinal therapy in this indication, we conducted a
multicenter phase II study in patients with relapsing primary
CBCL to evaluate the efficacy and safety of intra-lesional
administrations of TG1042 in this population of patients. Our
results show high response rates of CBCL to intra-lesional
TG1042 treatment as well as good tolerability making this gene-
therapy based immunotherapy a reasonable option for these
cutaneous lymphomas.
Materials and Methods
Study design and patients
The protocol for this trial and supporting checklist are available
as supporting information; see Checklist S1 and Protocol S1. This
open label single arm study was approved by the local institutional
ethical committees and the national authorities for biosafety in
Switzerland, France and USA, and conducted in accordance with
the ethical principles of the Declaration of Helsinki, in compliance
with the approved protocol and its amendments, and good clinical
practice principles. The study obtained approval from national
health agencies in all countries where it took place and from the
respective ethics committees or institutional review boards for all
participating centers (University Hospital, Nantes, France; Uni-
versity Hospital, Zurich, Switzerland; Stanford University School
of Medicine, California, USA; Northwestern University Medical
School, Chicago, Illinois, USA; M.D. Anderson Cancer Center,
Houston, Texas, USA; Saint Eloi Hospital, Montpellier, France).
The study was conducted in accordance with the ethical principles
of the Helsinki Declaration, the International Conference of
Harmonization Good Clinical Practice guidelines and the local
regulatory requirements. Written informed consent was obtained
from each patient. The clinical trial was registered under
ClinicalTrials.gov with the identifier NCT00394693. To be
eligible for the study, the selected patients had to fulfill the
following most important inclusion criteria: histologically con-
firmed diagnosis of primary CBCL, including (according to
WHO/EORTC classification 2005 [4]) primary cutaneous
marginal zone B-cell lymphoma, primary cutaneous follicle center
B-cell lymphoma, primary cutaneous diffuse large B-cell lympho-
ma other than leg type (for all countries except in France, as a
request from local authorities) and T-cell/histiocyte-rich B-cell
lymphoma; relapse or active disease after at least one first line of
treatment by radiotherapy or other standard therapy. Patients with
primary cutaneous diffuse large B-cell lymphoma, leg-type, were
excluded. All prior treatments for CBCL had to be stopped 4
weeks prior to patient enrollment into the study. Disease
progression requiring other forms of specific antitumor therapy
during the study was a cause for discontinuation from the study.
An independent pathology review of the biopsy samples obtained
before and after treatment was performed. No discrepancy was
found between initial diagnosis given by the investigator and the
one that was given by the independent pathology review.
Study drug, administration procedure
Patients received from the participating investigators intrale-
sional injections of TG1042 at the dose of 561010 viral particles
(vp) per lesion into up to six lesions treated simultaneously on days
1, 8 and 15. Patients received no treatment during the fourth week
of the cycle. The cycle length was 4 weeks (1 cycle), at the end of
the cycle the tumors were evaluated for response (Day 29). In the
absence of progression an additional cycle was to be delivered up
to a maximum of four cycles. In the event of local response and
consequent disappearance of the initially-treated lesion(s), the
investigator was to decide if applicable whether or not to treat a
second series of one or several additional lesion(s) that were not
previously treated.
Tumor response, quality of life and safety evaluations
The primary objective of the study was the response rate of the
treated lesions in the group of study participants. The response to
the treatment was defined in a given patient as the best objective
tumor response, which was recorded from the first cycle evaluation
until the last follow up visit on study. The response was to be
confirmed by a repeated assessment performed no less than 4
weeks after the criteria for response were first met. Complete
response (CR) was defined as the clinical disappearance of all
treated lesions. Partial response (PR) was defined as the clinical
disappearance of at least half of all treated lesions. Minor response
(MR) was defined as a decrease of at least 50% in the sum of the
products of all treated lesions with the clinical disappearance of
less than half of all treated lesions. Progressive disease (PD) was
defined as an increase of at least 25% in the sum of the products of
all treated lesions. Stable disease (SD) was defined as any response
that did not meet the criteria for CR, PR, MR or PD. Total
response assessment used the same definitions applied to all the
lesions but also integrated for the definition of PD the appearance
of new cutaneous lesions, lymph nodes, hematological or visceral
involvement.
An evaluation of all lesions (treated and not treated) was
performed at baseline and on Day 29 of each cycle, at the last
treatment cycle visit and at each follow-up visit or up to tumor
progression. The treatment efficacy in patients that had shown a
CR as best objective tumor response was confirmed by patholog-
ical analysis of skin biopsies at the site of the treated lesions.
An independent histo-pathology review was performed on the
biopsies obtained from the 13 patients, in order to confirm the
initial diagnosis of primary cutaneous B-cell lymphomas and the
treatment efficacy of TG1042 for patients who achieved a CR.
Secondary endpoints included the assessment of safety as well as
quality of life
The condition of the patient was monitored for adverse events
(AEs) throughout the study by clinical safety assessments by the
investigator. The intensity of AEs was graded according to the
NCI-CTCAE version 3.0 (see the website http://ctep.cancer.gov/
protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
(accessed January 14th 2013)).
All patients were evaluated for quality of life using the
Dermatology Life Quality Index (DLQI) questionnaire at each
visit. The DLQI questionnaire allows a scoring from 0 to 30
corresponding respectively to no effect at all on patient’s life and
an extremely large effect on patient’s life [11]. A post-treatment
follow-up was performed on a monthly basis for the first 6 months
and then on a quarterly basis for one year or until progression.
Statistical design and analyses
The purpose of the trial was to reject the experimental
treatment from being further studied, if TG1042 was shown to
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be insufficiently active in the considered indication and to accept it
for further studying, if it was shown to be active. The study was
designed as a two-stage ‘optimum’ phase II trial with the following
assumptions: the inactivity cut-off was chosen equal to 50%, the
activity cut-off equal to 75%.
Hence the hypotheses of interest were H0: r#50% against HA:
r$75%, where r is the response rate. The type I error rate (a,
probability of accepting an insufficiently active treatment, a false
positive outcome) was set to 5%. The type II error rate (b,
probability of rejecting an active treatment, a false negative
outcome) was set to 10%. Under these assumptions, the first step of
the optimal design consisted in treating 13 evaluable patients, if at
most 7 responses were observed, the trial was to be stopped and
the drug declared insufficiently active. If at least 8 responses were
observed, the drug was to be declared active and additional
patients were to be treated up to a total of 41 evaluable patients
with the aim of obtaining a total of 26 responses to confirm
TG1042 is active. After the first step of the study achieved its
endpoint and showed a sufficient level of activity, the sponsor
Figure 1. Study profile.
doi:10.1371/journal.pone.0083670.g001
Table 1. Patient characteristics and clinical outcome.
Patient ID Gender Age
Disease
Subtype
Previous
Treatments Local Response
Global
Response Duration of Response (days)
Time to
Progression
(days)
1 M 66 PCFCL R, I PR PR 169 197
2 M 59 PCMZL I CR CR 189 231
3 M 46 PCLBCL R, C, I CR CR 1547 1602
4 F 40 PCMZL R CR SD 274+ 805+
5 M 58 PCFCL S, R PR PR 191+ 218+
6 F 40 PCMZL R, C NE NE NA 76+
7 F 39 PCFCL I CR PR 1366+ 1516+
8 M 30 PCMZL R, C, I PR PR 631 813
9 F 50 PCMZL R, C PR PR 624 707
10 M 58 PCFCL I CR SD 554+ 685+
11 M 80 PCFCL R, I CR SD 1150+ 1280+
12 M 57 PCMZL R, C SD PD NA 79+
13 F 70 PCFCL R, I CR CR 239+ 349
Response corresponds to the best response of the treated lesions observed during the study. Duration of response: Number of days between the documented best
response (CR, PR, MR) of treated lesions until the first date of PD is objectively documented or the date of the last visit if no progression (censored data).
Time to progression: Number of days between the date of inclusion until the first date of PD of the treated lesions is objectively documented or the date of the last visit
if no progression (censored data).
NA = Not applicable; NE = non evaluable; PR = partial response; SD = stable disease; CR = complete response.
PCFCL = Primary cutaneous follicle-center lymphoma, PCMZL = Primary cutaneous marginal zone lymphoma.
PCLBCL = Primary Cutaneous Diffuse Large B-cell Lymphoma, other than leg type
R = Radiotherapy, S = Surgery, C = Chemotherapy, I = Immunotherapy including interferon, imiquimod and rituximab.
‘‘+’’in seven patients means ongoing response or non-progression at the time of study database lock.
doi:10.1371/journal.pone.0083670.t001
Figure 2. Time to Progression TTP).
doi:10.1371/journal.pone.0083670.g002
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decided to not initiate the second step of the statistical design for
company reasons.
The Intent-To-Treat population (ITT) (N= 13) included all
patients enrolled in the study including the one non-evaluable
patient. The Per-Protocol population (PP) (N=12) included all
patients of the ITT population but excluded patients with major
protocol violations (0), the non-evaluable patients (1) and the
wrongly included patients (0). The Safety Population included all
patients enrolled in the study and who received at least one
injection of TG1042 (N= 13). The efficacy analyses were done on
ITT and PP populations. The ITT analysis was considered as the
primary analysis of the study. All data analyses were performed
using SASH version 8.1 or higher. The best response rates were
calculated with their exact 95% confidence interval using the
Pearson-Clopper method. Duration of response was calculated for
each patient with CR, PR or MR. The median time to progression
was determined by Kaplan-Meier method. Its 95% confidence
interval was calculated by the Brookmeyer-Crowley method.
Results
Study Population
Thirteen patients were enrolled and treated by seven study
centers between March 2007 and July 2008, last patient last visit
Figure 3. Examples of lesions before and after treatment with TG1042. Patient #2, PCMZL, before treatment (A) and after 7 months (B).
Patient #5, PCFCL, before treatment (C) and after 4 months (D). Patient #7, PCFCL, before treatment (E) and after 9 months (F).
doi:10.1371/journal.pone.0083670.g003
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was in January 2010 (Figure 1). Patient characteristics and
previous treatments are shown in Table 1.
Clinical Outcome
The primary efficacy endpoint on study was the response rate of
the treated lesions. Of the 13 patients treated with TG1042 intra-
tumoral injections 12 were evaluable for response to treatment, all
patients completed their follow-up as planned per-protocol. Eleven
(85%, CI95%: 55–98) evaluable patients in the intent-to-treat
population showed complete or partial response. Seven (54%)
patients had a complete response and 4 (31%) patients had a
partial response. One additional patient (8%) was considered as
having a stable disease after the treatment. The secondary efficacy
points of the study included duration of response for treated
lesions, global response rate of treated and non-treated lesions and
time-to-progression (summarized in Table 1). The median time to
first objective response was 3.2 months (rage 1–17.5 months). In
the seven patients who achieved a complete response the median
time to complete response was 4.3 months (range 1.4–17.5). The
median time to disease progression of the treated lesions was 23.5
months (range 6.5–26.4+ months) (Figure 2). Dermatology Life
Quality Index (DLQI) showed a trend toward an improvement,
the mean score was 2.1 at baseline (range 0–7) and decreased to
1.0 (range 0–3) after cycle 3. More precisely at baseline, the mean
score of 7 patients who completed the DLQI was 2.1, indicative of
a small effect on a patient’s life. At the end of each cycle (Day 29)
for up to 4 cycles, the mean score continued to decrease or
remained stable: 2.0 at the end of cycle 1 (n = 9), 1.5 (cycle 2;
n = 8), 1.0 (cycle 3; n= 8), and 1.2 (cycle 4; n= 5). The greatest
mean change from baseline in the treatment period was -1.2,
which was obtained at the end of cycle 3.
All reviewed skin biopsies showed an improvement of the lesions
after treatment, characterized by an important decrease of the
lymphoid infiltrate. Clinical examples of lesions before and after
treatment are shown in Figure 3.
Adverse Events
All 13 (100%) patients who received treatment with TG1042
were included in safety population. All patients experienced one or
more Adverse Event (AEs) that was considered possibly or
probably related to study drug (Table 2). One patient (No. 6)
was discontinued from the study due to AEs of influenza-like
illness, pyrexia, headache and skin blisters possibly related to
TG1042.
With the exception of a single grade 3 event (increased lipase
considered not related to TG1042 and which resolved without a
treatment) all AEs were mild or moderate (grade 1 or 2) in severity.
The most commonly reported AEs were fatigue (8/8 patients),
headache (6/7 patients), pyrexia (6/6 patients), injection site
irritation (5/5 patients), chills, influenza-like illness, injection site
erythema and injection site pain (4/4 patients each), all of which
were expected events associated with injections of TG1042. All
reported adverse drug reactions resolved after treatment discon-
tinuation. No clinically significant hematology or serum chemistry
laboratory abnormalities were reported by the investigators.
Discussion
This clinical study shows that repeated injections of TG1042
(adenovirus-IFNc) into CBCL lesions lead to a reliable partial or
total regression of the treated disease. This observation represents
evidence that gene delivery based immunotherapy is feasible and
can lead to sustained clinical tumor responses, which are of clinical
benefit. The clinical improvement was supported by the improve-
ment of the lesions seen at the pathological review of pre- and
post-treatment biopsies. As expected, most commonly observed
adverse events were injection site reactions and transient flu-like
syndromes of mild or moderate intensity, demonstrating a good
tolerability of the product.
The high response rate observed with TG1042 in this
population of patients with CBCL raises the question of the
mechanism of action of TG1042. It has been shown previously in
patients treated with TG1042 for cutaneous lymphomas that not
only the transgene IFNc is expressed, but also a type I IFN
response is induced due to the adenoviral vector itself. In addition,
this type of combined type I (IFNa) and type II (IFNc) IFN-
response was predictive of the objective (partial and complete)
clinical responses observed in the course of the treatment with
TG1042 [12]. Similar activity can also be expected in CBCL, as it
was described in other cancers such as melanoma [13,14,15],
breast cancer [15], prostate cancer [16], renal cell carcinoma [17]
and sarcoma [16] treated by gene therapy. A study performed in
melanoma using the same adenoviral vector with interleukin-2
instead of interferon-c showed regression of metastatic melanoma
lesions in 6 out of 21 patients treated at the same dose of 3.10 [12]
viral particles (vp) by injection [13].
This study has confirmed initial observation of the previous
clinical trial, in which patients with CBCL already displayed a
high response rate in general and as compared to what was
observed in patients with CTCL. The high responsiveness of
CBCL lesions to this approach in the absence of any cytotoxic
treatment implies a high sensitivity of this tumor type to type I and
II IFN-response. This argues in favor of immunologic approaches
for the treatment of CBCL especially, since the treatment options
for CBCL are rather limited and there are currently no registered
drugs for this indication. The most commonly used approaches are
still radiation therapy or surgery (see reference [7] for review),
which show an initial response rate of up to 99%. However, due to
the natural history of the disease up to 50% of the patients relapse
in the decade following the initial treatment [18,19].
The anti-CD20 monoclonal antibody, rituximab, offers also a
new possibility of treatment in this type of lymphoma, it is more
indicated in patients with multifocal lesions and the optimal
treatment has not yet been well defined. In the literature,
Table 2. Adverse events reported.
Preferred Term
Number of
patients Number of events
Diarrhoea 3 13
Chills 4 11
Fatigue 8 17
Influenza like illness 4 17
Injection site erythema 4 10
Injection site irritation 5 6
Injection site pain 4 4
Pyrexia 6 17
Myalgia 3 18
Arthralgia 3 3
Headache 7 12
Only adverse events recorded in 3 patients or more have been listed in this
table. A total of 196 AEs have been recorded, 179 of them were considered
related to TG1042. All recorded adverse events were of grade 1 or 2 apart one
grade 3 increase in blood lipase not considered related to TG1042.
doi:10.1371/journal.pone.0083670.t002
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progression is observed in around 60% of cases with a median of
14.5 months. Intra lesional rituximab is an alternative to
perfusions using lower doses than those used for intravenous
therapy (less than 10%). The immediate response rate is high,
close to 100% but is associated with a high rate of early
recurrences, 42% in the year following treatment. The most
frequently adverse events observed with rituximab are fever, chills,
nausea, headache, urticaria and asthenia, which are mainly of
grade 1 or 2. However one of the main concerns with rituximab,
because of the long lasting complete depletion of B lymphocytes, is
the risk of serious viral infections and especially progressive
multifocal leukoencepahalopathy [20]. The side effects from the
available treatments as well as their relapse rate leave the room for
a treatment that would have good tolerability and could be easily
repeated. From this standpoint the gene therapy approach with
TG1042 evaluated in this study shows a favorable risk/benefit
ratio with a high response rate and a long duration of response
after treatment discontinuation. The adverse events are mild to
moderate and easily manageable. TG1042 could therefore be an
alternative to surgery or radiation therapy treatment or be used in
combination with these therapies to minimize risk of recurrence;
TG1042 could also be indicated in case of relapse. Further studies
are necessary to evaluate the efficacy of TG1042 in comparison or
in combination with standard treatment, such as radiotherapy.
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